Fate Therapeutics (FATE) Common Equity (2012 - 2026)

Fate Therapeutics' Common Equity history runs 15 years deep, the most recent figure standing at $179.7 million for Q1 2026.

• Quarterly Common Equity fell 37.69% year-over-year to $179.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $179.7 million (down 37.69% YoY) and the FY2025 annual result came in at $207.2 million, down 35.0% from the prior year.
• Common Equity was $179.7 million for Q1 2026 at Fate Therapeutics, down from $207.2 million in the prior quarter.
• Across five years, Common Equity topped out at $633.4 million in Q1 2022 and bottomed at $179.7 million in Q1 2026.
• A 5-year average of $386.9 million and a median of $397.0 million in 2024 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2024 — Common Equity slipped 9.31% — and 2026, when it tumbled 37.69%.
• Fate Therapeutics' Common Equity stood at $483.9 million in 2022, then dropped by 23.87% to $368.4 million in 2023, then declined by 13.49% to $318.7 million in 2024, then tumbled by 35.0% to $207.2 million in 2025, then decreased by 13.26% to $179.7 million in 2026.
• Business Quant data shows FATE's Common Equity at $179.7 million in Q1 2026, $207.2 million in Q4 2025, and $234.1 million in Q3 2025.